- Policy
- Comprehensive Health Insurance Plan to be released soon
- by Lee, Jeong-Hwan Jan 3, 2024 05:40am
- With the government's plan to announce the 2nd National Health Insurance Comprehensive Plan being postponed from December last year to January of this year, the pharmaceutical industry is anxiously awaiting what policy direction will be included in the new plan regarding drug expenditures. The pharmaceutical industry’s wishes are that th
- Policy
- Subject drugs with claims over KRW 5 bil for price nego
- by Lee, Tak-Sun Jan 3, 2024 05:40am
- A study has shown that more drugs need to be subject to PVA negotiations due to the expanded scope of use. In other words, the current standard, which sets the expected additional claims amount in the KRW 10 billion range needs to be expanded to KRW 5 billion, and drugs with an expected increase rate of more than 100 % should also be su
- Company
- New antibiotic to be listed for reimb, following Zerbaxa
- by Eo, Yun-Ho Jan 3, 2024 05:40am
- Zavicefta, the next-generation antibiotic, is progressing towards reimbursement listing. According to the industry, Pfizer Pharmaceutical Korea is currently in the final round of discussions with the National Health Insurance Service (NHIS) to settle the reimbursement pricing negotiations for its Zavicefta Inj (ceftazidime·avibactam).
- Company
- ‘Drug pricing and reimb' needs most regulatory improvement
- by Chon, Seung-Hyun Jan 3, 2024 05:40am
- CEOs of both domestic and multinational pharmaceutical companies alike identified 'drug prices and reimbursement as in need of most regulatory improvement. CEOs of multinational pharmaceutical companies only gave a 2-point range satisfaction score in terms of satisfaction with Korea’s drug pricing and reimbursement regulations. This indica
- Policy
- 430K osteoporotic fractures in 2022, a steep rise over 20 yr
- by Lee, Tak-Sun Jan 2, 2024 05:45am
- There has been a yearly increment of 7.8% in patients with fractures due to osteoporosis, marking a staggering 346% increase compared to 20 years ago. Joint research conducted by National Health Insurance Service (NHIS) (Chariman: Jung Ki Suck) and The Korean Society for Bone and Mineral Research (Chariman: Ha Yong-Chan) has presented researc
- Policy
- 5-year relative survival rate of cancer 72.1% in 2021
- by Lee, Jeong-Hwan Jan 2, 2024 05:45am
- The five-year relative survival rate for cancer patients increased by 6.6% points in 10 years and has become 72.1%. In Korea, thyroid cancer was the most common, followed by colorectal, lung, and stomach cancers. On December 28th, the Ministry of Health and Welfare (Minister Kyoo-Hong Cho) and the Central Cancer Registry Cancer (National Can
- Company
- SK Chemicals ends copromotion agreement with Eli Lilly
- by Lee, Tak-Sun Jan 2, 2024 05:45am
- SK Chemicals announced that its copromotion agreement with Lilly Korea for the antidepressant Cymbalta Cap (duloxetine hydrochloride) and the migraine treatment Emgality (galcanezumab-gnlm) has been brought to an end. Cymbalta is the number one selling antidepressant on the market. Sales of Emgality have also been rising since last year'
- Company
- CMV treatment Livtencity lands in Big 5 hospitals in KOR
- by Eo, Yun-Ho Jan 2, 2024 05:45am
- Livtencity, a cytomegalovirus (CMV) treatment, is nearing prescription at tertiary general hospitals. According to industry sources, Takeda Pharmaceuticals Korea’s Livtencity (maribavir) has recently passed the Drug Committee (DC) of the “Big 5” hospitals, including Seoul National University Hospital, Samsung Seoul Hospital, Seoul St
- Policy
- Revising the PE exemption system… focuses on 'deferral'
- by Lee, Tak-Sun Jan 2, 2024 05:44am
- The ‘Pharmacoeconomic Evaluation Exemption System', which was first implemented in 2015, will be completely transformed in the new year. In the future, the system will defer rather than exempt companies from submitting required data, increasing the possibility of drugs being evaluated after listing. According to the industry on Dece
- Company
- Celltrion merges and launches with founder’s son as leader
- by Kim, Jin-Gu Dec 29, 2023 05:40am
- Celltrion’s Chair of the Board, Jin-Seok Seo, the eldest son of Celltrion’s Chairman Emeritus Jung-jin Seo, will helm the newly merged Celltrion. The new CEO Seo will lead the company in a 3-person representative system with Hyung-Ki Kim, current CEO of Celltrion, and Hyung-Ki Kim, former CEO of Celltrion Healthcare. Celltrion annou
